{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:55:06Z","timestamp":1794470106642,"version":"4.9.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","annalsthoracicsurgery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.athoracsur.2024.11.010","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T23:08:30Z","timestamp":1736464110000},"page":"495-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-9537","authenticated-orcid":false,"given":"Mara B.","family":"Antonoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle G.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai V.","family":"Salfity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Kotova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Taylor","family":"Ripley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso L.","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumil G.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir Y.","family":"Elamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Donington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W. Awori","family":"Hayanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2024.11.010_bib1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib2","doi-asserted-by":"crossref","first-page":"S992","DOI":"10.1016\/j.annonc.2022.07.1101","article-title":"973MO KEYNOTE-189 5-year update: first-line pembrolizumab (pembro)+ pemetrexed (pem) and platinum vs placebo (pbo)+ pem and platinum for metastatic nonsquamous NSCLC","volume":"33","author":"Garassino","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J\u00a0Thoracic Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib4","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non\u2013small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib5","series-title":"The MD Anderson Manual of Medical Oncology","article-title":"Chapter 24: Non\u2013Small Cell Lung Cancer: General Principles, Management of Localized Disease, and Treatment of Metastatic Disease without Oncogene Drivers","author":"Altan","year":"2022"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib6","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cllc.2019.07.007","article-title":"Improved overall survival with comprehensive local consolidative therapy in synchronous oligometastatic non-small-cell lung cancer","volume":"21","author":"Mitchell","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2379-x","article-title":"Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer","volume":"16","author":"Fleckenstein","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.radonc.2006.09.006","article-title":"Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)","volume":"81","author":"Khan","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jso.27165","article-title":"The \u201cnew\u201d oligometastatic disease state and associated therapies in non-small cell lung cancer: a narrative review","volume":"127","author":"Na","year":"2023","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib12","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.athoracsur.2024.11.010_bib13","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1200\/JCO.2020.38.15_suppl.9624","article-title":"BRIGHTSTAR: a pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-na\u00efve ALK-rearranged advanced NSCLC","volume":"38","author":"Elamin","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib14","unstructured":"ClinicalTrials.gov. Randomized Trial of Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study. Randomized Phase III Trial of Local Consolidation Therapy NCT03410043. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03410043"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib15","unstructured":"ClinicalTrials.gov. Randomized Phase III Trial of Local Consolidatio Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR). NCT03391869. https:\/\/clinicaltrials.gov\/study\/NCT03391869"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jtcvs.2023.09.048","article-title":"Surgery for oligometastatic non-small cell lung cancer","volume":"167","author":"Antonoff","year":"2023","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jjco\/hyq044","article-title":"Clinical outcomes of stereotactic brain and\/or body radiotherapy for patients with oligometastatic lesions","volume":"40","author":"Inoue","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.lungcan.2010.05.003","article-title":"Surgical treatment of oligometastatic non-small cell lung cancer","volume":"69","author":"Pfannschmidt","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib19","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1002\/cncr.26611","article-title":"Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease","volume":"118","author":"Salama","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jtcvs.2020.02.134","article-title":"Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer","volume":"161","author":"Mitchell","year":"2021","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib22","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jtcvs.2023.08.024","article-title":"Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease","volume":"167","author":"Deboever","year":"2024","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib24","first-page":"420","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen","year":"2018","journal-title":"J\u00a0Med Libr Assoc"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib25","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation [published correction appears in BMJ. 2016;354:i4086]","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib27","author":"Wells"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib28","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"Cochrane Bias Methods Group, & Cochrane Statistical Methods Group. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib29","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib30","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1001\/jama.2011.597","article-title":"IOM sets out \u201cgold standard\u201d practices for creating guidelines, systematic reviews","volume":"305","author":"Kuehn","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib32","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/CIR.0000000000000312","article-title":"Further evolution of the ACC\/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"133","author":"Halperin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib33","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jtcvs.2017.01.003","article-title":"The American Association for Thoracic Surgery\/Society of Thoracic Surgeons position statement on developing clinical practice documents","volume":"153","author":"Bakaeen","year":"2017","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib34","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.athoracsur.2014.01.052","article-title":"A\u00a0prospective study of surgical procedures for patients with oligometastatic non-small cell lung cancer","volume":"98","author":"Endo","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib36","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/cancers13081893","article-title":"Management of synchronous extrathoracic oligometastatic non-small cell lung cancer","volume":"13","author":"Jones","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib37","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.21037\/jtd-21-997","article-title":"Prognostic value of surgical intervention in advanced lung adenocarcinoma: a population-based study","volume":"13","author":"Zhu","year":"2021","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2017.11.021","article-title":"Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: a national analysis","volume":"115","author":"Yang","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.9702","article-title":"Comparison of survival rates after a combination of local treatment and systemic therapy vs systemic therapy alone for treatment of stage IV non-small cell lung cancer","volume":"2","author":"Uhlig","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib40","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jtcvs.2023.04.034","article-title":"Surgical management of non-small cell lung cancer with limited metastatic disease involving only the brain","volume":"167","author":"Kumar","year":"2024","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.lungcan.2018.09.021","article-title":"Local ablative treatment for synchronous single organ oligometastatic lung cancer-a propensity score analysis of 180 patients","volume":"125","author":"Frost","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib42","article-title":"Lobectomy can improve the survival of patients with non-small cell lung cancer with lung oligometastatic","volume":"8","author":"Wang","year":"2021","journal-title":"Front Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib43","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1759-7714.14312","article-title":"Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: a retrospective observational study","volume":"13","author":"Chen","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.lungcan.2014.06.001","article-title":"Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival","volume":"85","author":"Gray","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib45","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ijrobp.2014.07.012","article-title":"Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy","volume":"90","author":"Sheu","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2021.02.001","article-title":"A\u00a0risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis","volume":"154","author":"Spaggiari","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib47","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/ejcts\/ezz384","article-title":"Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis","volume":"57","author":"Opitz","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib48","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.21037\/jtd.2018.11.125","article-title":"Surgery of primary non-small cell lung cancer with oligometastasis: analysis of 172 cases","volume":"10","author":"Wang","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib49","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1186\/s12885-019-6216-x","article-title":"Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib50","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.athoracsur.2021.04.057","article-title":"Sequence for surgical resection of primary lung tumor for oligometastatic non-small cell lung cancer","volume":"113","author":"Shyr","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib51","doi-asserted-by":"crossref","first-page":"310","DOI":"10.21037\/jtd.2017.02.21","article-title":"Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis","volume":"9","author":"Li","year":"2017","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib52","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4143\/crt.2022.329","article-title":"Role of local treatment for oligometastasis: a comparability-based meta-analysis","volume":"54","author":"Rim","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib53","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/JS9.0000000000000339","article-title":"Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis","volume":"109","author":"Rim","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib54","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.cllc.2018.09.010","article-title":"Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations","volume":"20","author":"Hu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cllc.2018.09.015","article-title":"Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC)","volume":"20","author":"Elamin","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib56","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume":"13","author":"Xu","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib57","article-title":"Local therapy treatment conditions for oligometastatic non-small cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5606\/tgkdc.dergisi.2019.15427","article-title":"Results of surgical resection in lung cancer with synchronous brain metastasis","volume":"27","author":"Baysungur","year":"2019","journal-title":"Turk Gogus Kalp Damar Cerrahisi Derg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib59","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.athoracsur.2014.03.028","article-title":"Metastasectomy for synchronous solitary non-small cell lung cancer metastases","volume":"98","author":"T\u00f6nnies","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib60","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jtcvs.2012.05.051","article-title":"Surgery for oligometastatic non\u2013small cell lung cancer: Long-term results from a single center experience","volume":"144","author":"Congedo","year":"2012","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib61","article-title":"Factors affecting the survival of patients with oligometastatic non-small-cell lung cancer: a meta-analysis","volume":"2019","author":"Shi","year":"2019","journal-title":"Can Respir J"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib62","doi-asserted-by":"crossref","first-page":"775","DOI":"10.21037\/atm-21-540","article-title":"Surgical resection of primary tumors improved the prognosis of patients with bone metastasis of non-small cell lung cancer: a population-based and propensity score-matched study","volume":"9","author":"Tian","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib63","first-page":"2661","article-title":"Rescue surgery after immunotherapy\/tyrosine kinase inhibitors for initially unresectable lung cancer","volume":"14","author":"Galetta","year":"2022","journal-title":"Cancers(Basel)"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cllc.2011.05.006","article-title":"Results of a surgical resection for patients with stage IV non\u2013small-cell lung cancer","volume":"13","author":"Hanagiri","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib65","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2012.09.011","article-title":"Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage","volume":"78","author":"Collaud","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib66","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.21037\/tlcr-21-39","article-title":"Surgery for advanced-stage non-small cell lung cancer: lobectomy or sub-lobar resection?","volume":"10","author":"Hao","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2021.645870","article-title":"In spite of curative radical pulmonary procedures, lesser pulmonary resection shows more favorable prognosis in surgically treated NSCLC with synchronous isolated cranial oligometastases","volume":"8","author":"Kaba","year":"2021","journal-title":"Front Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib68","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/0218492315596463","article-title":"Survival outcomes for oligometastasis in resected non-small cell lung cancer","volume":"23","author":"Shimada","year":"2015","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib69","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ijrobp.2022.02.023","article-title":"Local consolidative therapy versus systemic therapy alone for metastatic non-small cell lung cancer: a systematic review and meta-analysis","volume":"114","author":"Wu","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib70","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non\u2013small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib71","series-title":"Optimal definition of oligometastasis showing survival benefits of local therapies during tyrosine kinase inhibitor treatment","first-page":"468","volume":"55","author":"Jang","year":"2023"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib72","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cllc.2023.03.008","article-title":"Salvage surgery after first-line alectinib for locally-advanced\/metastatic ALK-rearranged NSCLC: pathological response and perioperative results","volume":"24","author":"Lococo","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib73","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2017.08.006","article-title":"Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases","volume":"112","author":"Kwint","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib74","article-title":"Outcomes with local therapy and tyrosine kinase inhibition in patients with ALK\/ROS1\/RET-rearranged lung cancers","volume":"6","author":"Hubbeling","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib75","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.21037\/jtd.2019.09.17","article-title":"Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer","volume":"11","author":"Takahashi","year":"2019","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib76","doi-asserted-by":"crossref","first-page":"949","DOI":"10.55730\/1300-0144.5659","article-title":"Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis","volume":"53","author":"A\u00e7ikg\u00f6z","year":"2023","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib77","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231156387","article-title":"Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC","volume":"15","author":"Xuzhang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib78","first-page":"25","article-title":"Long-term surgical outcomes in oligometastatic non-small cell lung cancer: a single-center study","volume":"56","author":"Yoo","year":"2023","journal-title":"J\u00a0Chest Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib79","series-title":"Long-term survival in non\u2013small cell lung cancer patients with metachronous brain-only oligorecurrence who underwent definitive treatment","first-page":"150","volume":"54","author":"Kim","year":"2022"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib80","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/a-2028-7955","article-title":"Lung cancer resection after immunochemotherapy versus chemotherapy in oligometastatic nonsmall cell lung cancer","volume":"71","author":"Sponholz","year":"2023","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib81","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12262-012-0771-6","article-title":"Surgical treatment of extrapulmonary oligometastatic non-small cell lung cancer","volume":"77","author":"Pl\u00f6nes","year":"2015","journal-title":"Indian J Surg"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib82","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.21037\/jtd.2019.11.30","article-title":"Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience","volume":"11","author":"Zhang","year":"2019","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib83","doi-asserted-by":"crossref","first-page":"S2537","DOI":"10.21037\/jtd.2018.07.19","article-title":"The current state of oligometastatic and oligoprogressive non-small cell lung cancer","volume":"10","author":"Tumati","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thorsurg.2015.09.002","article-title":"Preoperative evaluation and indications for pulmonary metastasectomy","volume":"26","author":"Erhunmwunsee","year":"2016","journal-title":"Thorac Surg Clinics"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib85","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy292.130","article-title":"Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)","volume":"29","author":"Elamin","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib86","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/JTO.0b013e31827e1f83","article-title":"Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors","volume":"8","author":"Yu","year":"2013","journal-title":"J\u00a0Thoracic Oncol"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib87","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.lungcan.2021.09.019","article-title":"The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer","volume":"161","author":"Joosten","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib88","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib89","article-title":"Surgical complexity of pulmonary resections performed for oligometastatic NSCLC","volume":"3","author":"Antonoff","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.athoracsur.2024.11.010_bib90","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.xjon.2022.09.012","article-title":"Intraoperative challenges after induction therapy for non-small cell lung cancer: effect of nodal disease on technical complexity","volume":"12","author":"Feldman","year":"2022","journal-title":"JTCVS Open"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497524009603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497524009603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:32:41Z","timestamp":1739860361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497524009603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0003497524009603"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2024.11.010","relation":{},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2024.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by The Society of Thoracic Surgeons. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}